Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Fig. 3

Disease activity by DAS28(CRP), CDAI, and SDAI at baseline, 6 months, and 12 months (AO)

Note: The proportion of patients who achieved each level of disease activity was calculated using the number of patients with non-missing data for the disease activity score as the denominator. The sum of the proportions may not total 100.0% due to rounding

DAS28(CRP) remission: < 2.6; LDA: 2.6 ≤ DAS28(CRP) ≤ 3.2; MDA: 3.2 < DAS28(CRP) ≤ 5.1; HDA: > 5.1. CDAI remission: ≤ 2.8; LDA: 2.8 < CDAI ≤ 10.0; MDA: 10.0 < CDAI ≤ 22.0; HDA: > 22.0. SDAI remission: ≤ 3.3; LDA: 3.3 < SDAI ≤ 11.0; MDA: 11.0 < SDAI ≤ 26.0; HDA: > 26.0

AO as observed, BL baseline, CDAI clinical disease activity index, DAS28(CRP) disease activity score in 28 joints using C-reactive protein, HDA high disease activity, LDA low disease activity, MDA moderate disease activity, REM remission, SDAI simplified disease activity index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us